InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,249.92
(
0.25%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119891
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mblimon post# 4453

Thursday, 08/02/2007 11:27:05 PM

Thursday, August 02, 2007 11:27:05 PM

Post# of 19309
mlimon et al: Re: Patent expiration for CD20 IP

>so the time for DNA/BIIB's product to become generic is not that long<

I see now that you were referring to the 2014 date specified in today’s GTC PR. (I had previously assumed you were giving your own assessment of the CD20 patent life.)

The sentence of consequence in the PR is:

“The existing relevant CD20 antibody patents will expire by 2014.”

However, the word existing changes the complexion of the sentence substantially. As noted in #msg-21771786, BIIB says in its SEC filings that key CD20 patents for which it has applied have not yet issued. Moreover, if you search the patent applications that relate to therapeutic CD20 mAbs on the USPTO website, there are a great many hits.

In other words, despite the 2014 date in GTC’s PR, I highly doubt that the patent landscape for mAbs targeting CD20 is as simple as today’s PR makes it seem. Regards, Dew

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up